id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-4727-0006,FDA,FDA-2015-E-4727,"Determination of Regulatory Review Period for Purposes of Patent
Extension; Intercept Blood System for Plasma",Notice,Determinations,2017-07-11T04:00:00Z,2017,7,2017-07-11T04:00:00Z,2017-09-12T03:59:59Z,2017-07-11T14:06:30Z,2017-14454,0,0,090000648290d8f3
FDA-2015-E-4727-0005,FDA,FDA-2015-E-4727,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-07T04:00:00Z,2017,6,2017-06-07T04:00:00Z,,2017-06-07T16:20:34Z,,0,0,09000064826a207d